As of 2025-06-06, the Intrinsic Value of Calliditas Therapeutics AB (CALTX.ST) is (1,992.68) SEK. This CALTX.ST valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 208.00 SEK, the upside of Calliditas Therapeutics AB is -1,058.00%.
The range of the Intrinsic Value is (23,034.78) - (1,046.68) SEK
Based on its market price of 208.00 SEK and our intrinsic valuation, Calliditas Therapeutics AB (CALTX.ST) is overvalued by 1,058.00%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (23,034.78) - (1,046.68) | (1,992.68) | -1058.0% |
| DCF (Growth 10y) | (4,782.03) - (117,586.37) | (9,616.10) | -4723.1% |
| DCF (EBITDA 5y) | (511.85) - (1,079.00) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (2,485.91) - (5,805.83) | (1,234.50) | -123450.0% |
| Fair Value | -40.07 - -40.07 | -40.07 | -119.26% |
| P/E | (118.13) - (215.90) | (167.69) | -180.6% |
| EV/EBITDA | (46.29) - (96.72) | (66.41) | -131.9% |
| EPV | (84.02) - (145.14) | (114.58) | -155.1% |
| DDM - Stable | (157.82) - (6,992.61) | (3,575.21) | -1818.9% |
| DDM - Multi | (1,492.21) - (51,456.41) | (2,901.72) | -1495.1% |
| Market Cap (mil) | 12,467.52 |
| Beta | -0.02 |
| Outstanding shares (mil) | 59.94 |
| Enterprise Value (mil) | 12,678.51 |
| Market risk premium | 5.10% |
| Cost of Equity | 5.69% |
| Cost of Debt | 22.07% |
| WACC | 6.87% |